Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

TRML

Tourmaline Bio (TRML)

Tourmaline Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TRML
DataHoraFonteTítuloCódigoCompanhia
07/06/202417:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TRMLTourmaline Bio Inc
07/06/202417:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
23/05/202408:10GlobeNewswire Inc.Tourmaline Bio to Present at the Jefferies Global Healthcare ConferenceNASDAQ:TRMLTourmaline Bio Inc
16/05/202408:00GlobeNewswire Inc.Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY TrialNASDAQ:TRMLTourmaline Bio Inc
13/05/202417:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TRMLTourmaline Bio Inc
13/05/202408:00GlobeNewswire Inc.Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
02/04/202408:00GlobeNewswire Inc.Avalo Therapeutics Appoints Biotech Leaders to Board of DirectorsNASDAQ:TRMLTourmaline Bio Inc
19/03/202408:00GlobeNewswire Inc.Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:TRMLTourmaline Bio Inc
27/02/202409:30GlobeNewswire Inc.Tourmaline Bio to Present at Upcoming Investor ConferencesNASDAQ:TRMLTourmaline Bio Inc
14/02/202423:08Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TRMLTourmaline Bio Inc
14/02/202422:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:TRMLTourmaline Bio Inc
01/02/202410:00GlobeNewswire Inc.Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceNASDAQ:TRMLTourmaline Bio Inc
29/01/202418:01GlobeNewswire Inc.Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesNASDAQ:TRMLTourmaline Bio Inc
26/01/202418:08Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TRMLTourmaline Bio Inc
25/01/202409:00GlobeNewswire Inc.Tourmaline Bio Announces Pricing of Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
24/01/202418:05GlobeNewswire Inc.Tourmaline Bio Announces Proposed Public Offering of Common StockNASDAQ:TRMLTourmaline Bio Inc
08/01/202409:00GlobeNewswire Inc.Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)NASDAQ:TRMLTourmaline Bio Inc
15/12/202318:00GlobeNewswire Inc.Tourmaline Bio added to the NASDAQ Biotechnology IndexNASDAQ:TRMLTourmaline Bio Inc
14/12/202309:30GlobeNewswire Inc.Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the BoardNASDAQ:TRMLTourmaline Bio Inc
23/10/202319:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TRMLTourmaline Bio Inc
19/10/202318:37GlobeNewswire Inc.Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 MillionNASDAQ:TRMLTourmaline Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TRML